Atherosclerosis-targeted liposome nanocarrier delivery system and preparation method therefor
US-2024424132-A1 · Dec 26, 2024 · US
Compounds useful for treating cancer
US9108919B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9108919-B2 |
| Application number | US-201314087762-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 22, 2013 |
| Priority date | Jun 12, 2009 |
| Publication date | Aug 18, 2015 |
| Grant date | Aug 18, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method of preventing, inhibiting, or treating cancer that includes contacting a cell with at least one compound of formula (Ia) or a pharmaceutically acceptable salt thereof: where: R independently represents a hydrogen atom, a halogen atom, a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a —NO 2 group, a —NR 1 R 2 group, or a (C 1 -C 3 )alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C 1 -C 3 )alkyl group, a —NO 2 group, a (C 1 -C 3 )alkoxy group, or a —NR 1 R 2 group; and R 1 and R 2 are a hydrogen atom or a (C 1 -C 3 )alkyl group.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating breast cancer, pancreatic cancer, prostate cancer, lung cancer, non-small cell lung cancer, thyroid cancer, liver cancer, and kidney cancer, comprising: contacting a cell with at least one compound of formula (Ia) or a pharmaceutically acceptable salt thereof: wherein: R″ is a hydrogen atom or a (C 1 -C 4 )alkyl group; R i…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
- A61K31/4709Primary
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
- C07D403/12Primary
Chemistry & Metallurgy · mapped topic
- C07D215/38Primary
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9108919B2 cover?
- A method of preventing, inhibiting, or treating cancer that includes contacting a cell with at least one compound of formula (Ia) or a pharmaceutically acceptable salt thereof: where: R independently represents a hydrogen atom, a halogen atom, a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a —NO 2 g…
- Who is the assignee on this patent?
- Ct Nationale De Rech Scient, Inst Curie, Splicos Soc, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4709. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).